Export

ATC codes: L01AA06
EMLc
Indication
Ewing sarcoma of bone and articular cartilage of unspecified sites ICD11 code: 2C22.Z
INN
Ifosfamide
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IV: 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection
EML status history
First added in 2009 (TRS 958)
Changed in 2015 (TRS 994)
Sex
All
Age
Also recommended for children
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for Ewing sarcoma was specifically endorsed. Additionally, ifosfamide was added on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Ewing sarcoma is attached.